The First New Way to Fight Herpes in 30 Years Just Got the Green Light
The FDA just approved the first herpes antiviral with a new mechanism of action in nearly 30 years. It's not for cold sores; it's for immunocompromised patients who ran out of options, and the clinical data is striking.
For nearly three decades, doctors fighting herpes simplex virus have been stuck with essentially the same weapon: acyclovir and its close cousins. Different brand names, same basic trick. If the virus figured out how to dodge that trick, patients were left with a couple of toxic IV drugs and a whole lot of hope.
On October 9, 2026, the FDA finally handed them something new.
A Drug That Attacks From a Different Angle
The agency approved Hovilpri (pritelivir), a 100 mg oral tablet from Asahi Kasei, for immunocompromised adults whose herpes sores haven't responded to the standard antivirals: acyclovir, valacyclovir, or famciclovir. It's the first FDA-approved herpes therapy with a genuinely new mechanism of action in almost 30 years.
To understand why that matters, think of it like this. Acyclovir and its relatives are like bouncers who stand at the club's front door (the viral DNA polymerase) and need a special wristband from the virus (an enzyme called thymidine kinase) to even do their job. If the virus mutates and stops handing out wristbands, the bouncers are useless.
Pritelivir skips the wristband entirely. It targets the helicase-primase complex, a molecular machine the virus uses at an earlier step to unwind its DNA before copying it. No wristband required. That means pritelivir can work even when the virus has learned to resist the old drugs, because it's blocking a completely different part of the replication process.
The Patients Who Had Nowhere Else to Turn
This approval isn't aimed at the millions of otherwise healthy people who get cold sores. It's for a smaller, much sicker group: immunocompromised patients whose herpes infections become chronic, painful, and sometimes disfiguring because their immune systems can't help fight back.
We're talking about people recovering from bone marrow transplants, organ transplant recipients on immunosuppressive drugs, and patients with advanced HIV. In these populations, resistance to acyclovir and its relatives isn't rare.
When acyclovir stops working, the options get grim. Foscarnet and cidofovir can sometimes help, but both require IV infusion and come loaded with serious side effects, including kidney damage. Imagine telling a patient who just survived a stem cell transplant that their best remaining herpes treatment might wreck their kidneys. That's the gap pritelivir was designed to fill.
More from this issue
View full issue →
Deals & M&A6 min read
Merck Just Spent $10 Billion on a Lung Drug. Here's Why.
Merck is dropping $10 billion to buy Verona Pharma and its first-in-class COPD drug, ensifentrine. With Keytruda's $33 billion revenue stream facing patent expiration in 2028, this deal is less about lungs and more about survival.
Clinical & Regulatory
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
